Daiken Biomedical Co., Ltd. (TPE:7780)

Daiken Biomedical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	337.87	106.58	160.35	90.17
Depreciation & Amortization	6.95	4.21	0.92	0.1
Provision & Write-off of Bad Debts	0.02	0.88	0	0
Other Operating Activities	46.42	-23.94	2.25	19.36
Change in Accounts Receivable	-42.84	-26.19	-14.65	-2.51
Change in Inventory	-170.3	16.95	-84.29	-121.33
Change in Accounts Payable	78.09	25.36	15.6	34.09
Change in Unearned Revenue	2.93	-22.97	8.77	5.57
Change in Other Net Operating Assets	13.45	-29.12	16.24	16.12
Operating Cash Flow	272.59	51.75	105.21	41.58
Operating Cash Flow Growth	426.73%	-50.81%	153.01%	-
Capital Expenditures	-0.39	-1.25	-	-
Sale (Purchase) of Intangibles	-3.4	-1.97	-	-0.05
Investment in Securities	-3,026	92.12	-61.41	-
Other Investing Activities	-5.68	-4.8	-0.56	-31.9
Investing Cash Flow	-3,035	84.09	-61.96	-31.95
Short-Term Debt Issued	120	470	183.83	33
Long-Term Debt Issued	-	-	65	127.36
Total Debt Issued	120	470	248.83	160.36
Short-Term Debt Repaid	-20	-628	-58.83	-
Long-Term Debt Repaid	-3.25	-121.24	-49.42	-24.36
Total Debt Repaid	-23.25	-749.24	-108.26	-24.36
Net Debt Issued (Repaid)	96.75	-279.24	140.58	136
Issuance of Common Stock	4,313	1,000	-	-
Common Dividends Paid	-589.23	-3.08	-140.46	-
Financing Cash Flow	3,820	717.68	0.12	136
Foreign Exchange Rate Adjustments	39.17	-0.86	-	-
Net Cash Flow	1,097	852.66	43.36	145.63
Free Cash Flow	272.21	50.5	105.21	41.58
Free Cash Flow Growth	439.02%	-52.00%	153.01%	-
Free Cash Flow Margin	14.36%	3.71%	8.84%	4.70%
Free Cash Flow Per Share	0.41	0.12	0.47	0.27
Cash Interest Paid	-	6	3.36	1.18
Cash Income Tax Paid	-	56.96	32.74	-
Levered Free Cash Flow	68.82	171.51	15.47	-
Unlevered Free Cash Flow	69.19	175.26	17.57	-
Change in Working Capital	-118.67	-35.99	-58.33	-68.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.